Information about Invega (Paliperidone ER)
Invega is an extended-release formulation of paliperidone, an atypical antipsychotic. It is primarily used for the treatment of schizophrenia and schizoaffective disorder. The extended-release formulation enables dosing just once a day.
Product Highlights
- Treatment of schizophrenia in both adults and adolescents (aged 12 to 17).
- Treatment of schizoaffective disorder in adults.
Key Ingredient
Key Benefits
- Helps reduce symptoms of psychosis, such as hallucinations and delusions.
- May improve mood and social functioning.
- Generally well-tolerated, with fewer extrapyramidal side effects compared to typical antipsychotics.
- Once-daily dosing simplifies treatment regimens.
Direction of Use
- Invega is taken orally, with or without food.
- It is usually prescribed at a starting dose, which may be adjusted based on individual response and tolerability.
- Consistent dosing time each day is recommended for optimal results.
Safety Concerns
- There is a risk of metabolic side effects, such as weight gain and elevated blood sugar levels.
- Possible extrapyramidal symptoms (EPS), though typically less than with first-generation antipsychotics.
- Risk of tardive dyskinesia with long-term use.
- Monitoring for increased cholesterol and triglyceride levels is advisable.
Avoid Invega (Paliperidone ER) If
- You have a known allergy to paliperidone or any component of the formulation.
- You are taking certain medications that may interact, including other CNS depressants.
- You have a history of severe cardiovascular issues or conditions that may be worsened by the drug.
- You have severe renal impairment without appropriate dose adjustment.
